HIGHLIGHTS
- who: Wen Bao and colleagues from the Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China have published the article: PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis, in the Journal: PPAR Research of 21/04/2021
- what: (1) Both fenofibrate and octreotide acetate exert their antihyperlipidemic pancreatitis activity by inhibiting the NF-κB signaling pathway, and their therapeutic effects are synergistic [8] [9] (2) Compared with octreotide acetate alone, fenofibrate combined with octreotide acetate has a better therapeutic effect and is . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.